Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Inhibiting myeloperoxidase prevents onset and reverses established high fat diet -induced microvascular insulin resistance.

Chai W, Aylor K, Liu Z, Gan LM, Michaëlsson E, Barrett E.

Am J Physiol Endocrinol Metab. 2019 Oct 8. doi: 10.1152/ajpendo.00203.2019. [Epub ahead of print]

PMID:
31593502
2.

Stimulation of alpha 7 nicotinic acetylcholine receptor (α7nAChR) inhibits atherosclerosis via immunomodulatory effects on myeloid cells.

Ulleryd MA, Mjörnstedt F, Panagaki D, Yang LJ, Engevall K, Gutiérrez S, Wang Y, Gan LM, Nilsson H, Michaëlsson E, Johansson ME.

Atherosclerosis. 2019 Aug;287:122-133. doi: 10.1016/j.atherosclerosis.2019.06.903. Epub 2019 Jun 15.

PMID:
31260875
3.

Inhibition of MPO (Myeloperoxidase) Attenuates Endothelial Dysfunction in Mouse Models of Vascular Inflammation and Atherosclerosis.

Cheng D, Talib J, Stanley CP, Rashid I, Michaëlsson E, Lindstedt EL, Croft KD, Kettle AJ, Maghzal GJ, Stocker R.

Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1448-1457. doi: 10.1161/ATVBAHA.119.312725. Epub 2019 May 2.

PMID:
31043077
4.

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.

Gan LM, Lagerström-Fermér M, Ericsson H, Nelander K, Lindstedt EL, Michaëlsson E, Kjaer M, Heijer M, Whatling C, Fuhr R.

Br J Clin Pharmacol. 2019 Apr;85(4):762-770. doi: 10.1111/bcp.13855. Epub 2019 Feb 18.

5.

Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation.

Cao E, Lindgren A, Martinsson S, Hu L, Lindfors L, Sigfridsson K, Skantze U, Michaëlsson E, Trevaskis NL, Porter CJH.

J Control Release. 2019 Feb 28;296:29-39. doi: 10.1016/j.jconrel.2019.01.002. Epub 2019 Jan 3.

PMID:
30611901
6.

Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque.

Rashid I, Maghzal GJ, Chen YC, Cheng D, Talib J, Newington D, Ren M, Vajandar SK, Searle A, Maluenda A, Lindstedt EL, Jabbour A, Kettle AJ, Bongers A, Power C, Michaëlsson E, Peter K, Stocker R.

Eur Heart J. 2018 Sep 14;39(35):3301-3310. doi: 10.1093/eurheartj/ehy419.

PMID:
30219874
7.

Extracellular volume by cardiac magnetic resonance is associated with biomarkers of inflammation in hypertensive heart disease.

Pan JA, Michaëlsson E, Shaw PW, Kuruvilla S, Kramer CM, Gan LM, Keeley EC, Salerno M.

J Hypertens. 2019 Jan;37(1):65-72. doi: 10.1097/HJH.0000000000001875.

PMID:
30063646
8.

Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase.

Klinke A, Berghausen E, Friedrichs K, Molz S, Lau D, Remane L, Berlin M, Kaltwasser C, Adam M, Mehrkens D, Mollenhauer M, Manchanda K, Ravekes T, Heresi GA, Aytekin M, Dweik RA, Hennigs JK, Kubala L, Michaëlsson E, Rosenkranz S, Rudolph TK, Hazen SL, Klose H, Schermuly RT, Rudolph V, Baldus S.

JCI Insight. 2018 Jun 7;3(11). pii: 97530. doi: 10.1172/jci.insight.97530. eCollection 2018 Jun 7.

9.

Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs.

Dasa SSK, Suzuki R, Mugler E, Chen L, Jansson-Löfmark R, Michaëlsson E, Lindfors L, Klibanov AL, French BA, Kelly KA.

Nanomedicine. 2017 Nov;13(8):2565-2574. doi: 10.1016/j.nano.2017.07.005. Epub 2017 Jul 25.

10.

Determining myeloperoxidase activity and protein concentration in a single assay: Utility in biomarker and therapeutic studies.

Russell M, Prokoph N, Henderson N, Eketjäll S, Balendran CA, Michaëlsson E, Fidock M, Hughes G.

J Immunol Methods. 2017 Oct;449:76-79. doi: 10.1016/j.jim.2017.07.003. Epub 2017 Jul 13.

PMID:
28713008
11.

Determinants of coronary flow reserve in non-diabetic patients with chest pain without myocardial perfusion defects.

Westergren HU, Michaëlsson E, Blomster JI, Miliotis T, Svedlund S, Gan LM.

PLoS One. 2017 Apr 27;12(4):e0176511. doi: 10.1371/journal.pone.0176511. eCollection 2017.

12.

Nanocrystal formulations of a poorly soluble drug. 2. Evaluation of nanocrystal liver uptake and distribution after intravenous administration to mice.

Sigfridsson K, Skantze P, Skantze U, Svensson L, Löfgren L, Nordell P, Michaëlsson E, Smedsrød B, Fuglesteg B, Elvevold K, Lindfors L.

Int J Pharm. 2017 May 30;524(1-2):248-256. doi: 10.1016/j.ijpharm.2017.03.062. Epub 2017 Mar 31.

PMID:
28373104
13.

Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach.

Hage C, Michaëlsson E, Linde C, Donal E, Daubert JC, Gan LM, Lund LH.

Circ Cardiovasc Genet. 2017 Feb;10(1). pii: e001633. doi: 10.1161/CIRCGENETICS.116.001633.

PMID:
28100627
14.

Suppression of abdominal aortic aneurysm formation by AR-R17779, an agonist for the α7 nicotinic acetylcholine receptor.

Watanabe A, Ichiki T, Kojima H, Takahara Y, Hurt-Camejo E, Michaëlsson E, Sankoda C, Ikeda J, Inoue E, Tokunou T, Kitamoto S, Sunagawa K.

Atherosclerosis. 2016 Jan;244:113-20. doi: 10.1016/j.atherosclerosis.2015.11.006. Epub 2015 Nov 17.

PMID:
26613536
15.

Neutrophil NET formation is regulated from the inside by myeloperoxidase-processed reactive oxygen species.

Björnsdottir H, Welin A, Michaëlsson E, Osla V, Berg S, Christenson K, Sundqvist M, Dahlgren C, Karlsson A, Bylund J.

Free Radic Biol Med. 2015 Dec;89:1024-35. doi: 10.1016/j.freeradbiomed.2015.10.398. Epub 2015 Nov 4.

PMID:
26459032
16.

Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction.

Dasa SSK, Suzuki R, Gutknecht M, Brinton LT, Tian Y, Michaelsson E, Lindfors L, Klibanov AL, French BA, Kelly KA.

J Control Release. 2015 Dec 28;220(Pt A):556-567. doi: 10.1016/j.jconrel.2015.06.017. Epub 2015 Jun 27.

17.

Stimulation of α7 nicotinic acetylcholine receptor by AR-R17779 suppresses atherosclerosis and aortic aneurysm formation in apolipoprotein E-deficient mice.

Hashimoto T, Ichiki T, Watanabe A, Hurt-Camejo E, Michaëlsson E, Ikeda J, Inoue E, Matsuura H, Tokunou T, Kitamoto S, Sunagawa K.

Vascul Pharmacol. 2014 May-Jun;61(2-3):49-55. doi: 10.1016/j.vph.2014.03.006. Epub 2014 Mar 29.

PMID:
24685818
18.

Modelling of mouse experimental colitis by global property screens: a holistic approach to assess drug effects in inflammatory bowel disease.

Gottfries J, Melgar S, Michaëlsson E.

PLoS One. 2012;7(1):e30005. doi: 10.1371/journal.pone.0030005. Epub 2012 Jan 18.

19.

Intestinal, adipose, and liver inflammation in diet-induced obese mice.

Li H, Lelliott C, Håkansson P, Ploj K, Tuneld A, Verolin-Johansson M, Benthem L, Carlsson B, Storlien L, Michaëlsson E.

Metabolism. 2008 Dec;57(12):1704-10. doi: 10.1016/j.metabol.2008.07.029.

PMID:
19013294
20.

Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease.

Melgar S, Karlsson L, Rehnström E, Karlsson A, Utkovic H, Jansson L, Michaëlsson E.

Int Immunopharmacol. 2008 Jun;8(6):836-44. doi: 10.1016/j.intimp.2008.01.036. Epub 2008 Mar 7.

PMID:
18442787
21.

Intra-colonic administration of the TLR7 agonist R-848 induces an acute local and systemic inflammation in mice.

Karlsson A, Jägervall K, Utkovic H, Karlsson L, Rehnström E, Fredin MF, Gillberg PG, Jansson L, Michaëlsson E, Melgar S.

Biochem Biophys Res Commun. 2008 Mar 7;367(2):242-8. Epub 2007 Dec 18.

PMID:
18083110
22.

Local production of chemokines and prostaglandin E2 in the acute, chronic and recovery phase of murine experimental colitis.

Melgar S, Drmotova M, Rehnström E, Jansson L, Michaëlsson E.

Cytokine. 2006 Sep;35(5-6):275-83. Epub 2006 Nov 7.

PMID:
17088072
23.

Mice with experimental colitis show an altered metabolism with decreased metabolic rate.

Melgar S, Bjursell M, Gerdin AK, Svensson L, Michaëlsson E, Bohlooly-Y M.

Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G165-72. Epub 2006 Jul 13.

24.

Magnetic resonance imaging of experimental mouse colitis and association with inflammatory activity.

Larsson AE, Melgar S, Rehnström E, Michaëlsson E, Svensson L, Hockings P, Olsson LE.

Inflamm Bowel Dis. 2006 Jun;12(6):478-85.

PMID:
16775491
25.

Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation.

Melgar S, Karlsson A, Michaëlsson E.

Am J Physiol Gastrointest Liver Physiol. 2005 Jun;288(6):G1328-38. Epub 2005 Jan 6.

26.

Interference with CD28, CD80, CD86 or CD152 in collagen-induced arthritis. Limited role of IFN-gamma in anti-B7-mediated suppression of disease.

Tellander AC, Pettersson U, Runström A, Andersson M, Michaëlsson E.

J Autoimmun. 2001 Aug;17(1):39-50.

PMID:
11488636
27.
28.

CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts.

Olsson C, Riesbeck K, Dohlsten M, Michaëlsson E.

J Biol Chem. 1999 May 14;274(20):14400-5. Erratum in: J Biol Chem 1999 Jul 23;274(30):21490. Riebeck K [corrected to Riesbeck K].

29.

Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis.

Corthay A, Bäcklund J, Broddefalk J, Michaëlsson E, Goldschmidt TJ, Kihlberg J, Holmdahl R.

Eur J Immunol. 1998 Aug;28(8):2580-90.

30.

Receptor for alpha1-microglobulin on T lymphocytes: inhibition of antigen-induced interleukin-2 production.

Wester L, Michaëlsson E, Holmdahl R, Olofsson T, Akerström B.

Scand J Immunol. 1998 Jul;48(1):1-7.

31.

Biased dependency of CD80 versus CD86 in the induction of transcription factors regulating the human IL-2 promoter.

Olsson C, Michaëlsson E, Parra E, Pettersson U, Lando PA, Dohlsten M.

Int Immunol. 1998 Apr;10(4):499-506.

PMID:
9620606
32.

B cell presentation of cartilage type II collagen to T cells.

Holmdahl R, Michaëlsson E, Vestberg M.

Ann N Y Acad Sci. 1997 Apr 5;815:350-2. No abstract available.

PMID:
9186676
33.
34.

Systemic versus cartilage-specific expression of a type II collagen-specific T-cell epitope determines the level of tolerance and susceptibility to arthritis.

Malmström V, Michaëlsson E, Burkhardt H, Mattsson R, Vuorio E, Holmdahl R.

Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4480-5.

35.

Macrophages, but not dendritic cells, present collagen to T cells.

Michaëlsson E, Holmdahl M, Engström A, Burkhardt H, Scheynius A, Holmdahl R.

Eur J Immunol. 1995 Aug;25(8):2234-41.

PMID:
7545114
36.

Chronicity of tissue-specific experimental autoimmune disease: a role for B cells?

Holmdahl R, Vingsbo C, Mo JA, Michaëlsson E, Malmström V, Jansson L, Brunsberg U.

Immunol Rev. 1995 Apr;144:109-35. Review. No abstract available.

PMID:
7590810
37.

T cell recognition of carbohydrates on type II collagen.

Michaëlsson E, Malmström V, Reis S, Engström A, Burkhardt H, Holmdahl R.

J Exp Med. 1994 Aug 1;180(2):745-9.

38.

Expression of a transgenic class II Ab gene confers susceptibility to collagen-induced arthritis.

Brunsberg U, Gustafsson K, Jansson L, Michaëlsson E, Ahrlund-Richter L, Pettersson S, Mattsson R, Holmdahl R.

Eur J Immunol. 1994 Jul;24(7):1698-702.

PMID:
8026530
39.
40.
41.

Feeding methods for demented patients in end stage of life.

Michaelsson E, Norberg A, Norberg B.

Geriatr Nurs. 1987 Mar-Apr;8(2):69-73. No abstract available.

PMID:
3471688
42.

Supplemental Content

Loading ...
Support Center